Financière de Tubize SA (TUB.BR)
EUR 138.8
(-0.86%)
EUR 138.8
(-0.86%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 79.2 Million EUR | 65.69% |
| 2022 | 47.8 Million EUR | 138.51% |
| 2021 | 20.04 Million EUR | -40.2% |
| 2020 | 33.51 Million EUR | -61.25% |
| 2019 | 86.5 Million EUR | -39.35% |
| 2018 | 142.61 Million EUR | -25.78% |
| 2017 | 192.14 Million EUR | -20.27% |
| 2016 | 240.99 Million EUR | -15.52% |
| 2015 | 285.28 Million EUR | 54.75% |
| 2014 | 184.35 Million EUR | -17.03% |
| 2013 | 222.19 Million EUR | -13.0% |
| 2012 | 255.39 Million EUR | -10.89% |
| 2011 | 286.59 Million EUR | -8.96% |
| 2010 | 314.79 Million EUR | -8.09% |
| 2009 | 342.49 Million EUR | -4.74% |
| 2008 | 359.53 Million EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 223.43 Million EUR | 116.13% |
| 2005 | 103.38 Million EUR | -8.24% |
| 2004 | 112.66 Million EUR | -9.22% |
| 2003 | 124.1 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 31 Million EUR | 0.0% |
| 2023 FY | 79.2 Million EUR | 65.69% |
| 2023 Q2 | 47.9 Million EUR | 0.0% |
| 2023 Q4 | 79.2 Million EUR | 0.0% |
| 2022 Q2 | 45.21 Million EUR | 0.0% |
| 2022 FY | 47.8 Million EUR | 138.51% |
| 2022 Q4 | 47.8 Million EUR | 0.0% |
| 2021 FY | 20.04 Million EUR | -40.2% |
| 2021 Q4 | 20.04 Million EUR | 0.0% |
| 2021 Q2 | - EUR | 0.0% |
| 2020 FY | 33.51 Million EUR | -61.25% |
| 2020 Q4 | 33.51 Million EUR | 0.0% |
| 2020 Q2 | 32.01 Million EUR | 0.0% |
| 2019 Q2 | 86 Million EUR | 0.0% |
| 2019 Q4 | 86.5 Million EUR | 0.0% |
| 2019 FY | 86.5 Million EUR | -39.35% |
| 2018 Q4 | 142.61 Million EUR | 0.0% |
| 2018 FY | 142.61 Million EUR | -25.78% |
| 2018 Q2 | 139.11 Million EUR | 0.0% |
| 2017 Q2 | 190.41 Million EUR | 0.0% |
| 2017 FY | 192.14 Million EUR | -20.27% |
| 2017 Q4 | 192.14 Million EUR | 0.0% |
| 2016 FY | 240.99 Million EUR | -15.52% |
| 2016 Q2 | 238.38 Million EUR | 0.0% |
| 2016 Q4 | 240.99 Million EUR | 0.0% |
| 2015 FY | 285.28 Million EUR | 54.75% |
| 2015 Q2 | 144.32 Million EUR | 0.0% |
| 2015 Q4 | 285.28 Million EUR | 0.0% |
| 2014 Q4 | 184.35 Million EUR | 0.0% |
| 2014 Q2 | 209.07 Million EUR | 0.0% |
| 2014 FY | 184.35 Million EUR | -17.03% |
| 2013 FY | 222.19 Million EUR | -13.0% |
| 2013 Q4 | 222.19 Million EUR | 0.0% |
| 2013 Q2 | 240.05 Million EUR | 0.0% |
| 2012 Q4 | 255.39 Million EUR | 0.0% |
| 2012 Q2 | 297.62 Million EUR | 0.0% |
| 2012 FY | 255.39 Million EUR | -10.89% |
| 2011 Q2 | 274.44 Million EUR | 0.0% |
| 2011 FY | 286.59 Million EUR | -8.96% |
| 2011 Q4 | 286.59 Million EUR | 0.0% |
| 2010 Q2 | 303.09 Million EUR | 0.0% |
| 2010 FY | 314.79 Million EUR | -8.09% |
| 2010 Q4 | 314.79 Million EUR | 0.0% |
| 2009 Q4 | 342.49 Million EUR | 0.0% |
| 2009 FY | 342.49 Million EUR | -4.74% |
| 2008 FY | 359.53 Million EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 223.43 Million EUR | 116.13% |
| 2005 FY | 103.38 Million EUR | -8.24% |
| 2004 FY | 112.66 Million EUR | -9.22% |
| 2003 FY | 124.1 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -2236.283% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -42.795% |
| Adocia SA | 13.08 Million EUR | -505.134% |
| Aelis Farma SA | 4.03 Million EUR | -1861.367% |
| Biophytis S.A. | 8.27 Million EUR | -857.678% |
| Advicenne S.A. | 17.42 Million EUR | -354.519% |
| genOway Société anonyme | 7.23 Million EUR | -994.92% |
| IntegraGen SA | 1.12 Million EUR | -6941.659% |
| Medesis Pharma S.A. | 1.2 Million EUR | -6500.0% |
| Neovacs S.A. | 650 Thousand EUR | -12084.615% |
| NFL Biosciences SA | 62.17 Thousand EUR | -127284.437% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -1717.969% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -2815.152% |
| Sensorion SA | 2.86 Million EUR | -2660.749% |
| Theranexus Société Anonyme | 3.64 Million EUR | -2074.02% |
| TME Pharma N.V. | 1.16 Million EUR | -6692.453% |
| Valbiotis SA | 6.87 Million EUR | -1051.498% |
| TheraVet SA | 1.15 Million EUR | -6728.369% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -780.196% |
| argenx SE | 18.1 Million EUR | -337.441% |
| BioSenic S.A. | 28.16 Million EUR | -181.24% |
| Celyad Oncology SA | 902 Thousand EUR | -8680.488% |
| DBV Technologies S.A. | 13.01 Million USD | -508.36% |
| Galapagos NV | 9.59 Million EUR | -725.344% |
| Genfit S.A. | 70.17 Million EUR | -12.856% |
| GeNeuro SA | 7.73 Million EUR | -923.547% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -1396.033% |
| Innate Pharma S.A. | 39.89 Million EUR | -98.531% |
| Inventiva S.A. | 37.4 Million EUR | -111.725% |
| MaaT Pharma SA | 14.07 Million EUR | -462.7% |
| MedinCell S.A. | 58.96 Million EUR | -34.326% |
| Nanobiotix S.A. | 50.56 Million EUR | -56.63% |
| Onward Medical N.V. | 16.87 Million EUR | -369.361% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -478.641% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -72.922% |
| Oxurion NV | 12.33 Million EUR | -542.127% |
| Pharming Group N.V. | 155.29 Million EUR | 49.0% |
| Poxel S.A. | 46.9 Million EUR | -68.87% |
| GenSight Biologics S.A. | 18.42 Million EUR | -329.781% |
| Transgene SA | 1.25 Million EUR | -6200.716% |
| UCB SA | 3.03 Billion EUR | 97.393% |
| Valneva SE | 208.81 Million EUR | 62.072% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -208321.053% |